State of Wyoming Buys New Shares in CureVac N.V. $CVAC

Key Points

• The State of Wyoming invested approximately $317,000 in CureVac N.V. by purchasing 114,273 shares, representing about 0.05% ownership in the company.
• CureVac's stock has recently received mixed analyst ratings, with UBS downgrading it from "strong-buy" to "neutral" and setting a new price target of $5.50.
• The company's recent quarterly earnings reported an EPS of ($0.30), which fell short of analysts' expectations of ($0.15), indicating challenges in revenue generation.

State of Wyoming purchased a new stake in shares of CureVac N.V. (NASDAQ:CVAC - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 114,273 shares of the company's stock, valued at approximately $317,000. State of Wyoming owned approximately 0.05% of CureVac at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of CVAC. Greenleaf Trust bought a new stake in CureVac during the 1st quarter worth approximately $31,000. Two Sigma Advisers LP bought a new stake in CureVac during the 4th quarter worth approximately $48,000. D. E. Shaw & Co. Inc. bought a new stake in CureVac during the 4th quarter worth approximately $66,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in CureVac by 14.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company's stock worth $81,000 after acquiring an additional 3,648 shares during the period. Finally, Ballentine Partners LLC increased its holdings in CureVac by 81.8% during the 1st quarter. Ballentine Partners LLC now owns 31,573 shares of the company's stock worth $88,000 after acquiring an additional 14,210 shares during the period. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

CureVac Trading Up 0.7%

Shares of CVAC stock traded up $0.04 on Friday, hitting $5.39. 479,822 shares of the company's stock traded hands, compared to its average volume of 608,366. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.16 and a current ratio of 6.17. CureVac N.V. has a one year low of $2.37 and a one year high of $5.72. The company's fifty day simple moving average is $5.43 and its 200 day simple moving average is $4.28. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of 5.61 and a beta of 2.53.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, August 21st. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.15). CureVac had a net margin of 38.21% and a return on equity of 29.57%. The business had revenue of $1.41 million for the quarter, compared to the consensus estimate of $4.27 million. Equities analysts forecast that CureVac N.V. will post 0.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CVAC. Jefferies Financial Group reaffirmed a "hold" rating and set a $5.00 target price (down previously from $7.00) on shares of CureVac in a report on Friday, June 13th. Citizens Jmp lowered shares of CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. JMP Securities reaffirmed a "market outperform" rating and set a $10.00 target price on shares of CureVac in a report on Wednesday, May 28th. Citigroup lowered shares of CureVac to a "market perform" rating in a report on Thursday, June 12th. Finally, UBS Group lowered shares of CureVac from a "strong-buy" rating to a "neutral" rating and decreased their price target for the stock from $12.00 to $5.50 in a report on Thursday, June 26th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $6.83.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.